-

Pfizer Declares Fourth-Quarter 2020 Dividend

Board of Directors approves quarterly cash dividend of $0.38 per share

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.: Breakthroughs that change patients’ lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Contacts

Pfizer Media Contact:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor Contact:
Chuck Triano
(212) 733-3901
Charles.E.Triano@pfizer.com

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Pfizer Media Contact:
Amy Rose
(212) 733-7410
Amy.Rose@pfizer.com

Pfizer Investor Contact:
Chuck Triano
(212) 733-3901
Charles.E.Triano@pfizer.com

More News From Pfizer Inc.

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases. “At Pfizer, we address some of the most urgent challenges i...

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy...

Pfizer Declares Fourth-Quarter 2026 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026. As part of its capital allocation strategy, Pfizer is committed to maintaining, and over the longer term, growing the dividend. The fourth-quarter 2026 cash dividend will be the 352nd consecutive quarterly dividend...
Back to Newsroom